(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                                  |                      |                  |                       |                                               |
|-------------------------------------------------------------------------|----------------------|------------------|-----------------------|-----------------------------------------------|
| Drug Name                                                               | Current<br>Drug Tier | New<br>Drug Tier | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| <b>EFFECTIVE 01/01/2023</b>                                             |                      |                  |                       |                                               |
| Bupivacaine HCl Inj 0.5%                                                | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Bupivacaine HCl Preservative Free (PF) Inj 0.5%                         | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Carnitor Solution 1 GM/10ML Oral                                        | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Carnitor TABLET 330 MG Oral                                             | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Caziant TABLET 0.1/0.125/0.15 - 0.025 MG Oral                           | 1                    | NF               | CMS Required Deletion | N/A                                           |
| Cefazolin Sodium For Inj 2 GM                                           | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Digox Tablet 125 MCG Oral                                               | 1                    | NF               | CMS Required Deletion | N/A                                           |
| Digox Tablet 250 MCG Oral                                               | 1                    | NF               | CMS Required Deletion | N/A                                           |
| Engerix-B Suspension 20 MCG/ML Injection                                | NF                   | 1 + BvD          | Formulary Enhancement | N/A                                           |
| Lactated Ringer's for Irrigation                                        | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Lindane Shampoo 1 % External                                            | 1                    | NF               | CMS Required Deletion | N/A                                           |
| Na Sulfate-K Sulfate-Mg Sulf<br>Solution 17.5-3.13-1.6 GM/177ML<br>Oral | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Nucala Solution Prefilled Syringe 40<br>MG/0.4ML Subcutaneous           | NF                   | 1 + PA           | Formulary Enhancement | N/A                                           |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                            |                      |                  |                       |                                               |
|-------------------------------------------------------------------|----------------------|------------------|-----------------------|-----------------------------------------------|
| Drug Name                                                         | Current<br>Drug Tier | New<br>Drug Tier | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| Pentacel SUSPENSION<br>RECONSTITUTED Intramuscular                | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Priorix Suspension Reconstituted<br>Subcutaneous                  | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Procalamine Solution 3 % Intravenous                              | 1 + BvD              | NF               | CMS Required Deletion | N/A                                           |
| Quadracel Suspension Prefilled<br>Syringe 0.5 ML Intramuscular    | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Recombivax HB SUSPENSION 5<br>MCG/0.5ML INJECTION                 | NF                   | 1 + BvD          | Formulary Enhancement | N/A                                           |
| Renacidin Sol                                                     | NF                   | 1 + BvD          | Formulary Enhancement | N/A                                           |
| Skyrizi Solution Cartridge 360<br>MG/2.4ML Subcutaneous           | NF                   | 1 + PA           | Formulary Enhancement | N/A                                           |
| Tenivac INJECTABLE 5-2 LFU<br>Intramuscular                       | NF                   | 1 + BvD          | Formulary Enhancement | N/A                                           |
| Ticovac Suspension Prefilled Syringe 1.2 MCG/0.25ML Intramuscular | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Water For Irrigation, Sterile Irrigation<br>Soln                  | NF                   | 1                | Formulary Enhancement | N/A                                           |
| YF-VAX INJECTABLE<br>Subcutaneous                                 | NF                   | 1                | Formulary Enhancement | N/A                                           |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                              |                      |                   |                       |                                               |
|-----------------------------------------------------|----------------------|-------------------|-----------------------|-----------------------------------------------|
| Drug Name                                           | Current<br>Drug Tier | New<br>Drug Tier  | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| <b>EFFECTIVE 02/01/2023</b>                         |                      |                   |                       |                                               |
| Adefovir Dipivoxil Tablet 10 MG<br>Oral             | 1 + QL 30 +<br>PA    | 1 + QL 30         | Formulary Enhancement | N/A                                           |
| Baraclude SOLUTION 0.05 MG/ML<br>ORAL               | 1 + QL 600 +<br>PA   | 1 + QL 600        | Formulary Enhancement | N/A                                           |
| Calquence Tablet 100 MG Oral                        | NF                   | 1 + QL 60 +<br>PA | Formulary Enhancement | N/A                                           |
| Caplyta Capsule 10.5 MG Oral                        | NF                   | 1                 | Formulary Enhancement | N/A                                           |
| Caplyta Capsule 21 MG Oral                          | NF                   | 1                 | Formulary Enhancement | N/A                                           |
| Daliresp Tablet 500 MCG Oral                        | 1                    | NF                | Formulary Update      | roflumilast tablet 500 mcg oral, 1            |
| Descovy Tablet 120-15 MG Oral                       | NF                   | 1                 | Formulary Enhancement | N/A                                           |
| Digitek TABLET 125 MCG ORAL                         | 1                    | NF                | CMS Required Deletion | N/A                                           |
| Enbrel Solution Reconstituted 25 MG<br>Subcutaneous | 1 + PA               | NF                | CMS Required Deletion | N/A                                           |
| Entecavir Tablet 0.5 MG Oral                        | 1 + QL 30 +<br>PA    | 1 + QL 30         | Formulary Enhancement | N/A                                           |
| Entecavir Tablet 1 MG Oral                          | 1 + QL 30 +<br>PA    | 1 + QL 30         | Formulary Enhancement | N/A                                           |
| Fingolimod HCl Capsule 0.5 MG Oral                  | NF                   | 1 + PA            | Formulary Enhancement | N/A                                           |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                     |                      |                      |                       |                                                  |
|------------------------------------------------------------|----------------------|----------------------|-----------------------|--------------------------------------------------|
| Drug Name                                                  | Current<br>Drug Tier | New<br>Drug Tier     | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier    |
| Furosemide SOLUTION 10 MG/ML INJECTION (4ML SYRINGE)       | 1                    | NF                   | CMS Required Deletion | N/A                                              |
| Gilenya CAPSULE 0.5 MG ORAL                                | 1 + PA               | NF                   | Formulary Update      | fingolimod hcl<br>capsule 0.5 mg<br>oral, 1 + PA |
| Hyftor Gel 0.2 % External                                  | NF                   | 1 + PA               | Formulary Enhancement | N/A                                              |
| Imbruvica Suspension 70 MG/ML<br>Oral                      | NF                   | 1 + QL 240 +<br>PA   | Formulary Enhancement | N/A                                              |
| Intron A Solution Reconstituted<br>18000000 UNIT Injection | 1 + PA               | NF                   | CMS Required Deletion | N/A                                              |
| Jynneos Suspension 0.5 ML<br>Subcutaneous                  | NF                   | 1                    | Formulary Enhancement | N/A                                              |
| Larissia Tablet 0.1-20 MG-MCG Oral                         | 1                    | NF                   | CMS Required Deletion | N/A                                              |
| Lenalidomide Capsule 2.5 MG Oral                           | NF                   | 1 + PA               | Formulary Enhancement | N/A                                              |
| Lenalidomide Capsule 20 MG Oral                            | NF                   | 1 + PA               | Formulary Enhancement | N/A                                              |
| Noxafil Packet 300 MG Oral                                 | NF                   | 1 + PA               | Formulary Enhancement | N/A                                              |
| Orkambi Packet 75-94 MG Oral                               | NF                   | 1 + QL 56/28<br>+ PA | Formulary Enhancement | N/A                                              |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                                                    |                      |                  |                       |                                                |
|-------------------------------------------------------------------------------------------|----------------------|------------------|-----------------------|------------------------------------------------|
| Drug Name                                                                                 | Current<br>Drug Tier | New<br>Drug Tier | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier  |
| Pentacel Suspension Reconstituted<br>Intramuscular (96-30-68-1-80-2-16-3-64-20 var units) | 1                    | NF               | CMS Required Deletion | N/A                                            |
| Pirfenidone Tablet 534 MG Oral                                                            | NF                   | 1 + PA           | Formulary Enhancement | N/A                                            |
| Pred-G SUSPENSION 0.3-1 %<br>OPHTHALMIC                                                   | 1                    | NF               | CMS Required Deletion | N/A                                            |
| ProAir HFA Aerosol Solution 108 (90 Base) MCG/ACT Inhalation                              | 1                    | NF               | CMS Required Deletion | N/A                                            |
| Revlimid Capsule 2.5 MG Oral                                                              | 1 + PA               | NF               | Formulary Update      | lenalidomide<br>capsule 2.5 mg<br>oral, 1 + PA |
| Revlimid Capsule 20 MG Oral                                                               | 1 + PA               | NF               | Formulary Update      | lenalidomide<br>capsule 20 mg<br>oral, 1 + PA  |
| Roflumilast Tablet 500 MCG Oral                                                           | NF                   | 1                | Formulary Enhancement | N/A                                            |
| Skyrizi (150 MG Dose) Prefilled<br>Syringe Kit 75 MG/0.83ML<br>Subcutaneous               | 1 + PA               | NF               | CMS Required Deletion | N/A                                            |
| Tazarotene Gel 0.05 % External                                                            | NF                   | 1 + PA           | Formulary Enhancement | N/A                                            |
| Tazarotene Gel 0.1 % External                                                             | NF                   | 1 + PA           | Formulary Enhancement | N/A                                            |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                                      |                      |                  |                       |                                               |
|-----------------------------------------------------------------------------|----------------------|------------------|-----------------------|-----------------------------------------------|
| Drug Name                                                                   | Current<br>Drug Tier | New<br>Drug Tier | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| Tazorac Gel 0.05 % External                                                 | 1 + PA               | NF               | Formulary Update      | tazarotene gel 0.05<br>% external, 1 + PA     |
| Tazorac Gel 0.1 % External                                                  | 1 + PA               | NF               | Formulary Update      | tazarotene gel 0.1<br>% external, 1 + PA      |
| Vemlidy TABLET 25 MG ORAL                                                   | 1 + PA               | 1                | Formulary Enhancement | N/A                                           |
| Venlafaxine Besylate ER Tablet<br>Extended Release 24 Hour 112.5 MG<br>Oral | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Zonisade Suspension 100 MG/5ML<br>Oral                                      | NF                   | 1                | Formulary Enhancement | N/A                                           |
| <b>EFFECTIVE 03/01/2023</b>                                                 |                      |                  |                       |                                               |
| Auvelity Tablet Extended Release 45-<br>105 MG Oral                         | NF                   | 1 + QL 60        | Formulary Enhancement | N/A                                           |
| Daliresp Tablet 250 MCG Oral                                                | 1                    | NF               | Formulary Update      | roflumilast tablet 250 mcg oral, 1            |
| Gleostine CAPSULE 10 MG ORAL                                                | NF                   | 1 + PA           | Formulary Enhancement | N/A                                           |
| Gleostine CAPSULE 100 MG ORAL                                               | NF                   | 1 + PA           | Formulary Enhancement | N/A                                           |
| Gleostine CAPSULE 40 MG ORAL                                                | NF                   | 1 + PA           | Formulary Enhancement | N/A                                           |
| Intron A Solution Reconstituted 10000000 UNIT Injection                     | 1 + PA               | NF               | CMS Required Deletion | N/A                                           |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                           |                      |                  |                       |                                               |
|------------------------------------------------------------------|----------------------|------------------|-----------------------|-----------------------------------------------|
| Drug Name                                                        | Current<br>Drug Tier | New<br>Drug Tier | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| Intron A Solution Reconstituted 50000000 UNIT Injection          | 1 + PA               | NF               | CMS Required Deletion | N/A                                           |
| Menest Tablet 2.5 MG Oral                                        | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Paser PACKET 4 GM ORAL                                           | 1                    | NF               | CMS Required Deletion | N/A                                           |
| Roflumilast Tablet 250 MCG Oral                                  | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Skyrizi Solution Cartridge 180<br>MG/1.2ML Subcutaneous          | NF                   | 1 + PA           | Formulary Enhancement | N/A                                           |
| <b>EFFECTIVE 04/01/2023</b>                                      |                      |                  |                       |                                               |
| Cefazolin Sol                                                    | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Digitek TABLET 250 MCG ORAL                                      | 1                    | NF               | CMS Required Deletion | N/A                                           |
| Esbriet Capsule 267 MG Oral                                      | 1 + PA               | NF               | Formulary Update      | pirfenidone<br>capsule 267 mg<br>oral, 1 + PA |
| Femynor Tablet 0.25-35 MG-MCG<br>Oral                            | 1                    | NF               | CMS Required Deletion | N/A                                           |
| Heplisav-B Solution Prefilled Syringe 20 MCG/0.5ML Intramuscular | NF                   | 1 + BvD          | Formulary Enhancement | N/A                                           |
| Krazati Tablet 200 MG Oral                                       | NF                   | 1 + PA           | Formulary Enhancement | N/A                                           |
| Leuprolide Acetate Injectable 22.5<br>MG Intramuscular           | NF                   | 1 + PA           | Formulary Enhancement | N/A                                           |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                                          |                      |                    |                       |                                               |
|---------------------------------------------------------------------------------|----------------------|--------------------|-----------------------|-----------------------------------------------|
| Drug Name                                                                       | Current<br>Drug Tier | New<br>Drug Tier   | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| Norvir SOLUTION 80 MG/ML<br>ORAL                                                | 1                    | NF                 | CMS Required Deletion | N/A                                           |
| Ozempic (0.25 or 0.5 MG/DOSE)<br>Solution Pen-Injector 2 MG/3ML<br>Subcutaneous | NF                   | 1                  | Formulary Enhancement | N/A                                           |
| Pirfenidone Capsule 267 MG Oral                                                 | NF                   | 1 + PA             | Formulary Enhancement | N/A                                           |
| Sodium Oxybate Solution 500<br>MG/ML Oral                                       | NF                   | 1 + QL 540 +<br>PA | Formulary Enhancement | N/A                                           |
| Sunlenca Tablet Therapy Pack 4 x 300 MG Oral                                    | NF                   | 1                  | Formulary Enhancement | N/A                                           |
| Sunlenca Tablet Therapy Pack 5 x 300 MG Oral                                    | NF                   | 1                  | Formulary Enhancement | N/A                                           |
| Veltassa PACKET 16.8 GM ORAL                                                    | NF                   | 1                  | Formulary Enhancement | N/A                                           |
| Veltassa PACKET 25.2 GM ORAL                                                    | NF                   | 1                  | Formulary Enhancement | N/A                                           |
| Veltassa Packet 8.4 GM Oral                                                     | NF                   | 1                  | Formulary Enhancement | N/A                                           |
| <b>EFFECTIVE 05/01/2023</b>                                                     |                      |                    |                       |                                               |
| Jaypirca Tablet 100 MG Oral                                                     | NF                   | 1 + QL 60 +<br>PA  | Formulary Enhancement | N/A                                           |
| Jaypirca Tablet 50 MG Oral                                                      | NF                   | 1 + QL 60 +<br>PA  | Formulary Enhancement | N/A                                           |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                      |                      |                  |                       |                                               |
|---------------------------------------------|----------------------|------------------|-----------------------|-----------------------------------------------|
| Drug Name                                   | Current<br>Drug Tier | New<br>Drug Tier | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| lamoTRIgine Kit 21 x 25 MG & 7 x 50 MG Oral | NF                   | 1                | Formulary Enhancement | N/A                                           |
| lamoTRIgine Kit 42 x 50 MG & 14x100 MG Oral | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Latuda Tablet 120 MG Oral                   | 1                    | NF               | Formulary Update      | lurasidone hcl<br>tablet 120 mg oral,<br>1    |
| Latuda Tablet 20 MG Oral                    | 1                    | NF               | Formulary Update      | lurasidone hcl<br>tablet 20 mg oral, 1        |
| Latuda Tablet 40 MG Oral                    | 1                    | NF               | Formulary Update      | lurasidone hcl<br>tablet 40 mg oral, 1        |
| Latuda Tablet 60 MG Oral                    | 1                    | NF               | Formulary Update      | lurasidone hcl<br>tablet 60 mg oral, 1        |
| Latuda Tablet 80 MG Oral                    | 1                    | NF               | Formulary Update      | lurasidone hcl<br>tablet 80 mg oral, 1        |
| Lurasidone HCl Tablet 120 MG Oral           | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Lurasidone HCl Tablet 20 MG Oral            | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Lurasidone HCl Tablet 40 MG Oral            | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Lurasidone HCl Tablet 60 MG Oral            | NF                   | 1                | Formulary Enhancement | N/A                                           |
| Lurasidone HCl Tablet 80 MG Oral            | NF                   | 1                | Formulary Enhancement | N/A                                           |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                      |                      |                       |                       |                                               |
|-------------------------------------------------------------|----------------------|-----------------------|-----------------------|-----------------------------------------------|
| Drug Name                                                   | Current<br>Drug Tier | New<br>Drug Tier      | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| Lytgobi (12 MG Daily Dose) Tablet<br>Therapy Pack 4 MG Oral | NF                   | 1 + QL 84/28<br>+ PA  | Formulary Enhancement | N/A                                           |
| Lytgobi (16 MG Daily Dose) Tablet<br>Therapy Pack 4 MG Oral | NF                   | 1 + QL 112/28<br>+ PA | Formulary Enhancement | N/A                                           |
| Lytgobi (20 MG Daily Dose) Tablet<br>Therapy Pack 4 MG Oral | NF                   | 1 + QL 140/28<br>+ PA | Formulary Enhancement | N/A                                           |
| Orserdu Tablet 345 MG Oral                                  | NF                   | 1 + PA                | Formulary Enhancement | N/A                                           |
| Orserdu Tablet 86 MG Oral                                   | NF                   | 1 + PA                | Formulary Enhancement | N/A                                           |
| Pirmella 1/35 Tablet 1-35 MG-MCG<br>Oral                    | 1                    | NF                    | CMS Required Deletion | N/A                                           |
| QUEtiapine Fumarate Tablet 150 MG<br>Oral                   | NF                   | 1                     | Formulary Enhancement | N/A                                           |
| Rezlidhia Capsule 150 MG Oral                               | NF                   | 1 + PA                | Formulary Enhancement | N/A                                           |
| Takhzyro Solution Prefilled Syringe 150 MG/ML Subcutaneous  | NF                   | 1 + PA                | Formulary Enhancement | N/A                                           |
| Vancomycin HCl IV Soln 2000<br>MG/400ML (Base Equivalent)   | NF                   | 1                     | Formulary Enhancement | N/A                                           |
| Ztalmy Suspension 50 MG/ML Oral                             | NF                   | 1                     | Formulary Enhancement | N/A                                           |
| <b>EFFECTIVE 06/01/2023</b>                                 |                      |                       |                       |                                               |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                       |                      |                   |                       |                                               |
|--------------------------------------------------------------|----------------------|-------------------|-----------------------|-----------------------------------------------|
| Drug Name                                                    | Current<br>Drug Tier | New<br>Drug Tier  | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| Azelastine HCl SOLUTION 0.15 % NASAL                         | 1                    | NF                | CMS Required Deletion | N/A                                           |
| Erleada Tablet 240 MG Oral                                   | NF                   | 1 + QL 30 +<br>PA | Formulary Enhancement | N/A                                           |
| Fluticasone-Salmeterol Aerosol 115-<br>21 MCG/ACT Inhalation | NF                   | 1                 | Formulary Enhancement | N/A                                           |
| Fluticasone-Salmeterol Aerosol 230-<br>21 MCG/ACT Inhalation | NF                   | 1                 | Formulary Enhancement | N/A                                           |
| Fluticasone-Salmeterol Aerosol 45-21<br>MCG/ACT Inhalation   | NF                   | 1                 | Formulary Enhancement | N/A                                           |
| Gentak Ointment 0.3 % Ophthalmic                             | 1                    | NF                | CMS Required Deletion | N/A                                           |
| Olopatadine HCl SOLUTION 0.2 %<br>Ophthalmic                 | 1                    | NF                | CMS Required Deletion | N/A                                           |
| Oxandrolone TABLET 10 MG ORAL                                | 1 + PA               | NF                | CMS Required Deletion | N/A                                           |
| Oxandrolone TABLET 2.5 MG<br>ORAL                            | 1 + PA               | NF                | CMS Required Deletion | N/A                                           |
| Prednicarbate Ointment 0.1 %<br>External                     | 1                    | NF                | CMS Required Deletion | N/A                                           |
| <b>EFFECTIVE 07/01/2023</b>                                  |                      |                   |                       |                                               |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                           |                      |                   |                       |                                               |  |
|------------------------------------------------------------------|----------------------|-------------------|-----------------------|-----------------------------------------------|--|
| Drug Name                                                        | Current<br>Drug Tier | New<br>Drug Tier  | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |  |
| Austedo XR Tablet Extended Release 24 Hour 12 MG Oral            | NF                   | 1 + QL 90 +<br>PA | Formulary Enhancement | N/A                                           |  |
| Austedo XR Tablet Extended Release<br>24 Hour 24 MG Oral         | NF                   | 1 + QL 60 +<br>PA | Formulary Enhancement | N/A                                           |  |
| Austedo XR Tablet Extended Release 24 Hour 6 MG Oral             | NF                   | 1 + QL 90 +<br>PA | Formulary Enhancement | N/A                                           |  |
| Drizalma Sprinkle Capsule Delayed<br>Release Sprinkle 20 MG Oral | 1 + QL 60            | NF                | CMS Required Deletion | N/A                                           |  |
| Drizalma Sprinkle Capsule Delayed<br>Release Sprinkle 30 MG Oral | 1 + QL 60            | NF                | CMS Required Deletion | N/A                                           |  |
| Drizalma Sprinkle Capsule Delayed<br>Release Sprinkle 40 MG Oral | 1 + QL 60            | NF                | CMS Required Deletion | N/A                                           |  |
| Drizalma Sprinkle Capsule Delayed<br>Release Sprinkle 60 MG Oral | 1 + QL 60            | NF                | CMS Required Deletion | N/A                                           |  |
| Emoquette Tablet 0.15-30 MG-MCG<br>Oral                          | 1                    | NF                | CMS Required Deletion | N/A                                           |  |
| Epivir HBV Solution 5 MG/ML Oral                                 | 1                    | NF                | CMS Required Deletion | N/A                                           |  |
| levoFLOXacin Solution 25 MG/ML<br>Intravenous                    | 1                    | NF                | CMS Required Deletion | N/A                                           |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                                            |                      |                   |                       |                                                     |  |
|-----------------------------------------------------------------------------------|----------------------|-------------------|-----------------------|-----------------------------------------------------|--|
| Drug Name                                                                         | Current<br>Drug Tier | New<br>Drug Tier  | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier       |  |
| Lumakras Tablet 320 MG Oral                                                       | NF                   | 1 + QL 90 +<br>PA | Formulary Enhancement | N/A                                                 |  |
| Noxafil Suspension 40 MG/ML Oral                                                  | 1 + PA               | NF                | Formulary Update      | posaconazole<br>suspension 40<br>mg/ml oral, 1 + PA |  |
| Ozempic (0.25 or 0.5 MG/DOSE)<br>Solution Pen-Injector 2 MG/1.5ML<br>Subcutaneous | 1                    | NF                | CMS Required Deletion | N/A                                                 |  |
| Posaconazole Suspension 40 MG/ML<br>Oral                                          | NF                   | 1 + PA            | Formulary Enhancement | N/A                                                 |  |
| Primidone Tablet 125 MG Oral                                                      | NF                   | 1                 | Formulary Enhancement | N/A                                                 |  |
| Rotarix Suspension Oral                                                           | NF                   | 1                 | Formulary Enhancement | N/A                                                 |  |
| traMADol HCl Solution 5 MG/ML<br>Oral                                             | NF                   | 1 + QL 2400       | Formulary Enhancement | N/A                                                 |  |
| Truseltiq (100MG Daily Dose)<br>Capsule Therapy Pack 100 MG Oral                  | 1 + QL 21/28<br>+ PA | NF                | CMS Required Deletion | N/A                                                 |  |
| Truseltiq (125MG Daily Dose)<br>Capsule Therapy Pack 100 & 25 MG<br>Oral          | 1 + QL 42/28<br>+ PA | NF                | CMS Required Deletion | N/A                                                 |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                         |                      |                   |                       |                                               |  |
|----------------------------------------------------------------|----------------------|-------------------|-----------------------|-----------------------------------------------|--|
| Drug Name                                                      | Current<br>Drug Tier | New<br>Drug Tier  | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |  |
| Truseltiq (50MG Daily Dose) Capsule<br>Therapy Pack 25 MG Oral | 1 + QL 42/28<br>+ PA | NF                | CMS Required Deletion | N/A                                           |  |
| Truseltiq (75MG Daily Dose) Capsule<br>Therapy Pack 25 MG Oral | 1 + QL 63/28<br>+ PA | NF                | CMS Required Deletion | N/A                                           |  |
| Zokinvy Capsule 50 MG Oral                                     | NF                   | 1 + PA            | Formulary Enhancement | N/A                                           |  |
| Zokinvy Capsule 75 MG Oral                                     | NF                   | 1 + PA            | Formulary Enhancement | N/A                                           |  |
| <b>EFFECTIVE 08/01/2023</b>                                    |                      |                   |                       |                                               |  |
| Abilify Asimtufii Prefilled Syringe 720 MG/2.4ML Intramuscular | NF                   | 1                 | Formulary Enhancement | N/A                                           |  |
| Abilify Asimtufii Prefilled Syringe 960 MG/3.2ML Intramuscular | NF                   | 1                 | Formulary Enhancement | N/A                                           |  |
| Celontin Capsule 300 MG Oral                                   | 1                    | NF                | Formulary Update      | methsuximide<br>capsule 300 mg<br>oral, 1     |  |
| Cimetidine HCl Solution 300<br>MG/5ML Oral                     | 1                    | NF                | CMS Required Deletion | N/A                                           |  |
| Dextrose Inj 70%                                               | NF                   | 1                 | Formulary Enhancement | N/A                                           |  |
| Filspari Tablet 200 MG Oral                                    | NF                   | 1 + QL 30 +<br>PA | Formulary Enhancement | N/A                                           |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES        |                      |                      |                       |                                               |  |
|-------------------------------|----------------------|----------------------|-----------------------|-----------------------------------------------|--|
| Drug Name                     | Current<br>Drug Tier | New<br>Drug Tier     | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |  |
| Filspari Tablet 400 MG Oral   | NF                   | 1 + QL 30 +<br>PA    | Formulary Enhancement | N/A                                           |  |
| Gefitinib Tablet 250 MG Oral  | NF                   | 1 + PA               | Formulary Enhancement | N/A                                           |  |
| Iressa Tablet 250 MG Oral     | 1 + PA               | NF                   | Formulary Update      | gefitinib tablet 250<br>mg oral, 1 + PA       |  |
| Kalydeco Packet 13.4 MG Oral  | NF                   | 1 + QL 56/28<br>+ PA | Formulary Enhancement | N/A                                           |  |
| Kynmobi Film 10 MG Sublingual | 1 + QL 150 +<br>PA   | NF                   | CMS Required Deletion | N/A                                           |  |
| Kynmobi Film 15 MG Sublingual | 1 + QL 150 +<br>PA   | NF                   | CMS Required Deletion | N/A                                           |  |
| Kynmobi Film 20 MG Sublingual | 1 + QL 150 +<br>PA   | NF                   | CMS Required Deletion | N/A                                           |  |
| Kynmobi Film 25 MG Sublingual | 1 + QL 150 +<br>PA   | NF                   | CMS Required Deletion | N/A                                           |  |
| Kynmobi Film 30 MG Sublingual | 1 + QL 150 +<br>PA   | NF                   | CMS Required Deletion | N/A                                           |  |
| Levo-T Tablet 100 MCG Oral    | 1                    | NF                   | CMS Required Deletion | N/A                                           |  |
| Levo-T TABLET 112 MCG ORAL    | 1                    | NF                   | CMS Required Deletion | N/A                                           |  |
| Levo-T Tablet 125 MCG Oral    | 1                    | NF                   | CMS Required Deletion | N/A                                           |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                  |                      |                     |                       |                                               |  |
|---------------------------------------------------------|----------------------|---------------------|-----------------------|-----------------------------------------------|--|
| Drug Name                                               | Current<br>Drug Tier | New<br>Drug Tier    | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |  |
| Levo-T TABLET 137 MCG ORAL                              | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Levo-T TABLET 150 MCG ORAL                              | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Levo-T TABLET 175 MCG ORAL                              | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Levo-T TABLET 200 MCG ORAL                              | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Levo-T Tablet 25 MCG Oral                               | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Levo-T TABLET 300 MCG ORAL                              | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Levo-T Tablet 50 MCG Oral                               | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Levo-T Tablet 75 MCG Oral                               | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Levo-T TABLET 88 MCG ORAL                               | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Mekinist Solution Reconstituted 0.05<br>MG/ML Oral      | NF                   | 1 + QL 1200 +<br>PA | Formulary Enhancement | N/A                                           |  |
| Methsuximide Capsule 300 MG Oral                        | NF                   | 1                   | Formulary Enhancement | N/A                                           |  |
| Nitisinone Capsule 20 MG Oral                           | NF                   | 1 + PA              | Formulary Enhancement | N/A                                           |  |
| Orfadin Capsule 20 MG Oral                              | 1 + PA               | NF                  | Formulary Update      | nitisinone capsule<br>20 mg oral, 1 + PA      |  |
| Quinapril-hydroCHLOROthiazide<br>Tablet 10-12.5 MG Oral | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Quinapril-hydroCHLOROthiazide<br>Tablet 20-12.5 MG Oral | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                        |                      |                      |                       |                                               |  |
|---------------------------------------------------------------|----------------------|----------------------|-----------------------|-----------------------------------------------|--|
| Drug Name                                                     | Current<br>Drug Tier | New<br>Drug Tier     | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |  |
| Quinapril-hydroCHLOROthiazide<br>Tablet 20-25 MG Oral         | 1                    | NF                   | CMS Required Deletion | N/A                                           |  |
| Tafinlar Tablet Soluble 10 MG Oral                            | NF                   | 1 + QL 900 +<br>PA   | Formulary Enhancement | N/A                                           |  |
| Trikafta Therapy Pack 100-50-75 & 75 MG Oral                  | NF                   | 1 + QL 56/28<br>+ PA | Formulary Enhancement | N/A                                           |  |
| Trikafta Therapy Pack 80-40-60 & 59.5 MG Oral                 | NF                   | 1 + QL 56/28<br>+ PA | Formulary Enhancement | N/A                                           |  |
| Turalio Capsule 125 MG Oral                                   | NF                   | 1 + PA               | Formulary Enhancement | N/A                                           |  |
| Vancomycin HCl Solution<br>Reconstituted 25 MG/ML Oral        | NF                   | 1                    | Formulary Enhancement | N/A                                           |  |
| <b>EFFECTIVE 09/01/2023</b>                                   |                      |                      |                       |                                               |  |
| Arexvy Suspension Reconstituted 120 MCG/0.5ML Intramuscular   | NF                   | 1                    | Formulary Enhancement | N/A                                           |  |
| Abrysvo Solution Reconstituted 120<br>MCG/0.5ML Intramuscular | NF                   | 1                    | Formulary Enhancement | N/A                                           |  |
| Clenpiq Solution 10-3.5-12 MG-GM - GM/175ML Oral              | NF                   | 1                    | Formulary Enhancement | N/A                                           |  |
| Dabigatran Etexilate Mesylate<br>Capsule 150 MG Oral          | NF                   | 1                    | Formulary Enhancement | N/A                                           |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                         |                      |                     |                       |                                               |  |
|----------------------------------------------------------------|----------------------|---------------------|-----------------------|-----------------------------------------------|--|
| Drug Name                                                      | Current<br>Drug Tier | New<br>Drug Tier    | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |  |
| Dabigatran Etexilate Mesylate<br>Capsule 75 MG Oral            | NF                   | 1                   | Formulary Enhancement | N/A                                           |  |
| Darunavir Tablet 600 MG Oral                                   | NF                   | 1                   | Formulary Enhancement | N/A                                           |  |
| Darunavir Tablet 800 MG Oral                                   | NF                   | 1                   | Formulary Enhancement | N/A                                           |  |
| Imbruvica Tablet 560 MG Oral                                   | 1 + QL 30 +<br>PA    | NF                  | CMS Required Deletion | N/A                                           |  |
| Lupron Depot-Ped (1-Month) Kit 7.5<br>MG Intramuscular         | NF                   | 1 + PA              | Formulary Enhancement | N/A                                           |  |
| Lupron Depot-Ped (3-Month) Kit<br>11.25 MG (Ped) Intramuscular | NF                   | 1 + PA              | Formulary Enhancement | N/A                                           |  |
| Lupron Depot-Ped (6-Month) Kit 45<br>MG Intramuscular          | NF                   | 1 + PA              | Formulary Enhancement | N/A                                           |  |
| Mekinist Solution Reconstituted 0.05 MG/ML Oral                | 1 + QL 1200 +<br>PA  | 1 + QL 1260 +<br>PA | Formulary Enhancement | N/A                                           |  |
| Prezista Tablet 600 MG Oral                                    | 1                    | NF                  | Formulary Update      | darunavir tablet<br>600 mg oral, 1            |  |
| Prezista Tablet 800 MG Oral                                    | 1                    | NF                  | Formulary Update      | darunavir tablet<br>800 mg oral, 1            |  |
| Procto-Pak Cream 1 % External                                  | 1                    | NF                  | CMS Required Deletion | N/A                                           |  |
| Turalio Capsule 200 MG Oral                                    | 1 + PA               | NF                  | CMS Required Deletion | N/A                                           |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                                                      |                      |                      |                       |                                                                             |
|---------------------------------------------------------------------------------------------|----------------------|----------------------|-----------------------|-----------------------------------------------------------------------------|
| Drug Name                                                                                   | Current<br>Drug Tier | New<br>Drug Tier     | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier                               |
| <b>EFFECTIVE 10/01/2023</b>                                                                 |                      |                      |                       |                                                                             |
| AmBisome Suspension Reconstituted 50 MG Intravenous                                         | 1 + BvD              | NF                   | Formulary Update      | amphotericin b liposome suspension reconstituted 50 mg intravenous, 1 + BvD |
| Amphotericin B Liposome Suspension Reconstituted 50 MG Intravenous                          | NF                   | 1 + BvD              | Formulary Enhancement | N/A                                                                         |
| Austedo XR Patient Titration Tablet<br>Extended Release Therapy Pack 6 &<br>12 & 24 MG Oral | NF                   | 1 + QL 42/28<br>+ PA | Formulary Enhancement | N/A                                                                         |
| Daybue Solution 200 MG/ML Oral                                                              | NF                   | 1 + QL 3600 +<br>PA  | Formulary Enhancement | N/A                                                                         |
| Midazolam HCl Solution 5 MG/ML Injection                                                    | NF                   | 1                    | Formulary Enhancement | N/A                                                                         |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                               |                      |                   |                       |                                                                          |  |
|----------------------------------------------------------------------|----------------------|-------------------|-----------------------|--------------------------------------------------------------------------|--|
| Drug Name                                                            | Current<br>Drug Tier | New<br>Drug Tier  | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier                            |  |
| Multiple Electro Type 1 pH 5.5<br>Solution Intravenous               | NF                   | 1 + BvD           | Formulary Enhancement | N/A                                                                      |  |
| Plasma-Lyte 148 Solution Intravenous                                 | 1 + BvD              | NF                | Formulary Update      | multiple electro<br>type 1 ph 5.5<br>solution<br>intravenous, 1 +<br>BvD |  |
| Talzenna Capsule 0.1 MG Oral                                         | NF                   | 1 + QL 30 +<br>PA | Formulary Enhancement | N/A                                                                      |  |
| Talzenna Capsule 0.35 MG Oral                                        | NF                   | 1 + QL 30 +<br>PA | Formulary Enhancement | N/A                                                                      |  |
| Zejula Tablet 100 MG Oral                                            | NF                   | 1 + QL 30 +<br>PA | Formulary Enhancement | N/A                                                                      |  |
| Zejula Tablet 200 MG Oral                                            | NF                   | 1 + QL 30 +<br>PA | Formulary Enhancement | N/A                                                                      |  |
| Zejula Tablet 300 MG Oral                                            | NF                   | 1 + QL 30 +<br>PA | Formulary Enhancement | N/A                                                                      |  |
| <b>EFFECTIVE 11/01/2023</b>                                          |                      |                   |                       |                                                                          |  |
| Cosentyx UnoReady Solution Auto-<br>Injector 300 MG/2ML Subcutaneous | NF                   | 1 + PA            | Formulary Enhancement | N/A                                                                      |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                                   |                      |                  |                       |                                                                      |  |
|--------------------------------------------------------------------------|----------------------|------------------|-----------------------|----------------------------------------------------------------------|--|
| Drug Name                                                                | Current<br>Drug Tier | New<br>Drug Tier | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier                        |  |
| Nevirapine ER Tablet Extended<br>Release 24 Hour 100 MG Oral             | 1                    | NF               | CMS Required Deletion | N/A                                                                  |  |
| Spiriva HandiHaler Capsule 18 MCG<br>Inhalation                          | 1                    | NF               | Formulary Update      | tiotropium bromide<br>monohydrate<br>capsule 18 mcg<br>inhalation, 1 |  |
| Tiotropium Bromide Monohydrate<br>Capsule 18 MCG Inhalation              | NF                   | 1                | Formulary Enhancement | N/A                                                                  |  |
| Vigadrone Tablet 500 MG Oral                                             | NF                   | 1 + PA           | Formulary Enhancement | N/A                                                                  |  |
| <b>EFFECTIVE 12/01/2023</b>                                              |                      |                  | ·                     |                                                                      |  |
| Breo Ellipta Aerosol Powder Breath<br>Activated 50-25 MCG/INH Inhalation | NF                   | 1                | Formulary Enhancement | N/A                                                                  |  |
| Breyna Aerosol 160-4.5 MCG/ACT Inhalation                                | NF                   | 1                | Formulary Enhancement | N/A                                                                  |  |
| Breyna Aerosol 80-4.5 MCG/ACT<br>Inhalation                              | NF                   | 1                | Formulary Enhancement | N/A                                                                  |  |
| Cefaclor Suspension Reconstituted<br>125 MG/5ML Oral                     | 1                    | NF               | CMS Required Deletion | N/A                                                                  |  |
| Cefaclor Suspension Reconstituted 375 MG/5ML Oral                        | 1                    | NF               | CMS Required Deletion | N/A                                                                  |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES                                           |                      |                      |                       |                                               |
|------------------------------------------------------------------|----------------------|----------------------|-----------------------|-----------------------------------------------|
| Drug Name                                                        | Current<br>Drug Tier | New<br>Drug Tier     | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |
| Lidocaine HCl Urethral/Mucosal<br>Prefilled Syringe 2 % External | NF                   | 1                    | Formulary Enhancement | N/A                                           |
| Lithium Solution 8 MEQ/5ML Oral                                  | NF                   | 1                    | Formulary Enhancement | N/A                                           |
| Ojjaara Tablet 100 MG Oral                                       | NF                   | 1 + QL 30 +<br>PA    | Formulary Enhancement | N/A                                           |
| Ojjaara Tablet 150 MG Oral                                       | NF                   | 1 + QL 30 +<br>PA    | Formulary Enhancement | N/A                                           |
| Ojjaara Tablet 200 MG Oral                                       | NF                   | 1 + QL 30 +<br>PA    | Formulary Enhancement | N/A                                           |
| Synjardy XR Tablet Extended Release 24 Hour 10-1000 MG Oral      | 1                    | NF                   | CMS Required Deletion | N/A                                           |
| Synjardy XR Tablet Extended Release 24 Hour 12.5-1000 MG Oral    | 1                    | NF                   | CMS Required Deletion | N/A                                           |
| Synjardy XR Tablet Extended Release 24 Hour 25-1000 MG Oral      | 1                    | NF                   | CMS Required Deletion | N/A                                           |
| Synjardy XR Tablet Extended Release 24 Hour 5-1000 MG Oral       | 1                    | NF                   | CMS Required Deletion | N/A                                           |
| Vanflyta Tablet 17.7 MG Oral                                     | NF                   | 1 + QL 56/28<br>+ PA | Formulary Enhancement | N/A                                           |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023

(1Tier)

Below is a list formulary changes for the benefit year 2023. This is not a complete list of drugs covered by the Part D plan. The formulary changes are reflected in the 2023 downloadable formulary on the *Kansas Health Advantage Choice* website.

For a complete list of drugs covered by *Kansas Health Advantage Choice*, please visit our website at <u>kansashealthadvantage.com</u>, or call Member Services at 1-800-399-7524, 8:00 am to 8:00 pm, 7 days a week from October 1<sup>st</sup> to March 31<sup>st</sup> and Monday to Friday from April 1<sup>st</sup> through September 30<sup>th</sup>. TTY/TDD users should call 1-833-312-0046.

BvD – Part B vs. Part D, NF - Non-Formulary, PA - Prior Authorization, QL – Quantity Limit per 30 Days, ST - Step Therapy

| 2023 FORMULARY CHANGES            |                      |                      |                       |                                               |  |
|-----------------------------------|----------------------|----------------------|-----------------------|-----------------------------------------------|--|
| Drug Name                         | Current<br>Drug Tier | New<br>Drug Tier     | Reason For Change     | Alternative Drug,<br>Alternative Drug<br>Tier |  |
| Vanflyta Tablet 26.5 MG Oral      | NF                   | 1 + QL 56/28<br>+ PA | Formulary Enhancement | N/A                                           |  |
| Xdemvy Solution 0.25 % Ophthalmic | NF                   | 1 + PA               | Formulary Enhancement | N/A                                           |  |

Formulary ID: 23562, Version 16

Last Updated: 11/21/2023 Effective date: 12/01/2023